GLP-1 drugs like Ozempic and Wegovy may help reduce the risk of cardiovascular disease and prevent more than 34,000 heart ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...
This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on ...
GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...
Karla Robinson, MD and Medical Editor at GoodRx discusses how GLP-1 receptor agonists work and their benefits.
The demand for medications like Ozempic continues to cause shortages for both those seeking weight loss and patients with ...
A large swath of insured Americans could be eligible for a popular class of weight loss and diabetes drugs. Meanwhile, Apple ...
A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery ...
While drugmakers Novo Nordisk and Eli Lilly assert that shortages of popular weight loss and diabetes medications Wegovy, Ozempic, Mounjaro and Zepbound are easing, many patients continue to face ...
There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...